China Heparin Industry Report, Dec. 2012

Size: px
Start display at page:

Download "China Heparin Industry Report, Dec. 2012"

Transcription

1 China Heparin Industry Report, Dec. 2012

2 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs. REPORT OBJECTIVES To establish a comprehensive, factual, annually updated and costeffective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts. To assist potential market entrants in evaluating prospective acquisition and joint venture candidates. To complement the organizations internal competitor information gathering efforts with strategic analysis, data interpretation and insight. To suggest for concerned investors in line with the current development of this industry as well as the development tendency. To help company to succeed in a competitive market, and METHODOLOGY Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies. INFORMATION SOURCES The primary information sources include China Customs, and China Pharmaceutical Industry Association etc. Copyright 2012 ResearchInChina understand the size and growth rate of any opportunity.

3 Abstract China, abundant in heparin raw materials, has become one of the world s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, China s export volume of heparin API was no more than tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period. 3.8% and 2.1% year-on-year respectively in Jan.-May, 2012, due to the improved quality of exported products as well as the low cardinal number of exported prices in the preceding year. Export Volume and Export Value Change of China Top 10 Heparin and Heparinate Exporters, Jan.-May, 2012 Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend Biochemical Pharmaceutical, which have ranked top 4 industrial players by export for several years in a row, with the combined export value making up more than 70% of China s total export value of heparin. There is no distinct change in terms of the export pattern. However, the export prices of China s top 10 heparin exporters witnessed a downward mobility in H1. Nevertheless, it was not the same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care Article Imp. & Exp. (Group), whose export prices increased by Copyright 2012ResearchInChina

4 Meanwhile, Chinese heparin API flagship enterprises including Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio- Pharma, Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical are projected to expand their capacities and improve the heparin industry chains. Among these tycoons, the first four ones have made IPO, while Nanjing King-Friend Biochemical Pharmaceutical is also preparing for IPO by accepting tutoring. According to public information issued by related enterprises, the heparin API capacity of China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand. However, with the improvement of R&D and technological strength, the competitiveness of made-in-china low molecular weight heparin preparation market is increasingly enhancing. A case in point is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecular weight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, with the sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales of RMB117 million in 2012H1, a year-on-year rise of 237.6%. Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in Copyright 2012ResearchInChina

5 1. Profile of Heparin Industry 1.1 Definition & Classification 1.2 Industry Chain 2. Operating Environment of Chinese Heparin Industry 2.1 Entry Barriers Policies Technical Requirements Capital Barrier 2.2 Supply and Demand in Global Market 2.3 Competition in Global Market 2.4 Global Market Forecast 3. Development of Heparin API Industry in China 3.1 Market Status Quo 3.2 Market Supply and Demand 3.3 Competitive Landscape 3.4 Import & Export Export Import 3.5 Development Outlook & Forecast 4. Development of Heparin Preparation Industry in China 4.1 Market Size 4.2 Competition Pattern 4.3 Market Segments Low Molecular Weight Heparin Preparation General Heparin Preparation 4.4 Development Outlook & Forecast 5. Key Chinese Heparin Manufacturers 5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd Profile Operation Revenue Structure Gross Margin R&D and Investment Clients and Suppliers Prospects 5.2 Changzhou Qianhong Bio-Pharma Co., Ltd Profile Operation Revenue Structure Gross Margin R&D and Investment Clients and Suppliers Heparin Business Prospects 5.3 Yantai Dongcheng Biochemicals Co., Ltd Profile Operation Revenue Structure Gross Margin Table of contents Clients and Suppliers Heparin Business Prospects 5.4 Hebei Changshan Biochemical Pharmaceutical Co., Ltd Profile Operation Revenue Structure Gross Margin R&D and Investment Clients and Suppliers Prospects 5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd Profile Operation Revenue Structure Gross Margin R&D and Investment Clients and Suppliers Heparin Business Prospects 5.6 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Profile Operation and Prospects 5.7 Wanbang Biopharmaceuticals Profile Operation and Prospects R&D and Investment

6 Application of Heparin Preparations Heparin Industry Chain Difference between Heparin Sodium API and Heparin Standardized Requirements Heparin Preparation Market Scale and YoY Growth Worldwide, Performance: Low Molecular Weight Heparin Preparation vs. General Heparin Preparation Global Heparin Preparation Distribution by Region, 2011 Heparin API Demand and YoY Growth Worldwide, Sales of Enoxaparin Worldwide by Product, Regulatory Exclusivity of Lovenox, as of late 2011 Global Heparin Preparation Market Scale, E Global Heparin API Demand, E Gross Margin of Major Heparin API Manufacturers in China, Capacity of Crude Heparin in China, Average Export Price of Heparin and Heparinate, Capacity of Major Heparin API Manufacturers in China, as of June 2012 Export Volume and Export Value of Heparin and Heparinate in China, Export Price of Heparin and Heparinate in China, Top 10 Export Destinations of Heparin and Heparinate in China by Value, Top 10 Heparin and Heparinate Enterprises in China by Export Value, 2011 Export Volume and Export Value of Heparin and Heparinate in China, Jan.-May, 2012 Import Volume, Import Value and Unite Price of Heparin and Heparinate in China, Planned / Ongoing Heparin Sodium API Projects in China, as of June 2012 Heparin Preparation Market Scale and YoY Growth of China, Market Share of Heparin Preparation Products in China, 2011 Main Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China Selected Charts Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations

7 Selected Charts China Low Molecular Weight Heparin Preparation Market Scale, Purchase Value of Low Molecular Weight Heparin Calcium of Chinese Representative Hospitals, Low Molecular Weight Heparin Preparation Imported Value of Representative Hospitals in 22 Chinese Cities, Competition Pattern of China Low Molecular Weight Heparin Calcium Market, 2009 Competition Pattern of China Low Molecular Weight Heparin Sodium Market, 2009 China Heparin Preparation Market Scale and YoY Growth, Assets and Net Income of Holding Subsidiaries under Hepalink, 2012H1 Revenue and Profit of Hepalink, Revenue of Hepalink by Product, Revenue of Hepalink by Region, Gross Margin of Hepalink by Product, R&D Investment and Proportion in Revenue of Hepalink, Revenue of Hepalink from the Top 5 Clients and Proportion, Revenue and Operating Income of Hepalink, E Assets, Revenue and Net Income of Subsidiaries under Qianhong Bio-Pharma, 2012H1 Revenue and Profit of Qianhong Bio-Pharma, Revenue of Qianhong Bio-Pharma by Product, Revenue of Qianhong Bio-Pharma by Region, Gross Margin of Qianhong Bio-Pharma by Product, R&D Investment and Proportion in Revenue of Qianhong Bio-Pharma, Scheduling of Planned/Ongoing Projects of Qianhong Bio-Pharma, as of June 2012 Top 5 Clients, Revenue Contribution and Proportion of Qianhong Bio-Pharma, 2011 Purchase Value of Qianhong Bio-Pharma s Top 5 Suppliers and Revenue Contribution of Qianhong Bio-Pharma s Top 5 Clients, Revenue and Gross Margin from Heparin Business of Qianhong Bio-Pharma, Revenue and Operating Income of Qianhong Bio-Pharma, Assets, Revenue and Net Income of Subsidiaries under Dongcheng Biochemicals, 2012H1

8 Revenue and Profit of Dongcheng Biochemicals, Revenue of Dongcheng Biochemicals by Product, Revenue of Dongcheng Biochemicals by Region, Gross Margin of Dongcheng Biochemicals by Product, R&D Investment and Proportion in Revenue of Dongcheng Biochemicals, Revenue and Gross Margin from Heparin Sodium API Business of Dongcheng Biochemicals, Heparin Sodium API Price of Dongcheng Biochemicals, Revenue Contribution of Dongcheng Biochemicals Top 5 Heparin Sodium API Clients, Scheduling of Heparin Sodium API Projects of Dongcheng Biochemicals, E Revenue and Profit of Dongcheng Biochemicals, E Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, Revenue of Hebei Changshan Biochemical Pharmaceutical by Product, Revenue of Hebei Changshan Biochemical Pharmaceutical by Region, Gross Margin of Hebei Changshan Biochemical Pharmaceutical by Product, R&D Investment and Proportion in Revenue of Hebei Changshan Biochemical Pharmaceutical, Product Research Scheduling of Hebei Changshan Biochemical Pharmaceutical, as of late 2011 Name List, Revenue Contribution and Proportion of Top 5 Clients of Hebei Changshan Biochemical Pharmaceutical, 2011 Heparin Product Certificates Won by Hebei Changshan Biochemical Pharmaceutical Overseas, as of late 2011 Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, E Revenue and Profit of Tianjin Chase Sun Pharmaceutical, Revenue of Tianjin Chase Sun Pharmaceutical by Product, Revenue of Tianjin Chase Sun Pharmaceutical by Region, Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, R&D Investment and Proportion in Revenue of Tianjin Chase Sun Pharmaceutical, Name List, Revenue Contribution and Proportion of Top 5 Clients of Tianjin Chase Sun Pharmaceutical, 2011 Selected Charts Name Room List, Purchase 502, Block Value 3, Tower and Proportion C, Changyuan of Top Tiandi 5 Suppliers Building, of No. Tianjin 18, Chase Suzhou Sun Street, Pharmaceutical, Haidian District, 2011Beijing, China

9 Revenue and Gross Margin from Heparin Business of Tianjin Chase Sun Pharmaceutical, Revenue and Operating Income of Tianjin Chase Sun Pharmaceutical, Assets and Net Income of Wanbang Biopharmaceuticals, Selected Charts

10 How to Buy You can place your order in the following alternative ways: 1.Order online at 2.Fax order sheet to us at fax number: your order to: 4. Phone us at / Choose type of format PDF (Single user license)..1,900 USD Hard copy.. 2,000 USD PDF (Enterprisewide license)... 3,000 USD Party A: Name: Address: Contact Person: Tel Fax Party B: Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina) Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China Contact Liao Yan Phone: Person: Fax: Bank details: Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,landianchang,haidian District,Beijing Bank Account No #: Routing No # : Bank SWIFT Code: COMMCNSHBJG Reports will be dispatched immediately once full payment has been received. Payment may be made by wire transfer or credit card via PayPal. Title Format Cost Total